Biogen Inc.BIIBNASDAQ
Loading
A mid-sized company, with solid profitability valued in line with the market.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 80.8% | 77.6%↓3.9% | 74.2%↓4.3% | 76.1%↑2.5% | 70.5%↓7.4% |
| Operating Margin | 25.4% | 28.4%↑11.7% | 21.3%↓24.9% | 25.7%↑20.7% | 19.1%↓25.6% |
| Net Margin | 14.2% | 29.9%↑111.4% | 11.8%↓60.6% | 16.9%↑42.9% | 13.2%↓21.8% |
| Earnings Yield | - | - | - | - | - |